SITC Scientific Publications News

SITC Publishes Commentary on a Crisis in Clinical Research

By SITC Scientific Publications News posted 4 days ago
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a commentary detailing what is being described as a Crisis in Clinical Research . The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic inefficiencies across critical ...
0 comments

ICI-Related Adverse Events CPG Updates v1.1 and v1.2 Now Available

By SITC Scientific Publications News posted 8 days ago
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments

Call for Comment - Surrogate Endpoints Virtual Summit Executive Summary

By SITC Scientific Publications News posted 15 days ago
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a comprehensive summary on the Surrogate Endpoints Virtual Summit , which was held on April 5, 2024. Surrogate endpoints have been instrumental for the advancement of immunotherapy, including dozens of approvals for a multitude of modalities across various disease states. These approvals are often facilitated through the use of endpoints that serve as surrogates ...
0 comments

SITC Publishes First Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy

By SITC Scientific Publications News posted 06-20-2024
On behalf of the SITC Board of Directors, we are pleased to announce the publication of a new manuscript titled, “ Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision ” available now in the Journal for ImmunoTherapy of Cancer (JITC) . This manuscript is the first in a JITC Special Series — The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer ...
0 comments

Breast Cancer CPG Update v1.2 Now Available

By SITC Scientific Publications News posted 06-11-2024
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the ...
0 comments

SITC Publishes Collaborative Manuscript on Recommendations for Tumor Mutational Burden Assay Validation and Reporting

By SITC Scientific Publications News posted 06-05-2024
On behalf of the Society for Immunotherapy of Cancer (SITC) and in collaboration with the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP), we are pleased to announce the publication of a new manuscript titled " Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society ...
0 comments

Gynecologic Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 05-25-2024
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments

SITC Publishes Commentary on Measurement and Interpretation of Essential Biomarkers in Early Clinical Trials

By SITC Scientific Publications News posted 05-22-2024
On behalf of the Society for Immunotherapy of Cancer (SITC), the SITC Biomarkers Committee, the SITC Pathology Committee, and the 2024 SITC Clinical Immuno-Oncology Network ( SCION ) faculty, we are pleased to announce the publication of a commentary on measurement and interpretation of essential biomarkers in early clinical trials . Immunotherapy of cancer is now a mainstay of modern oncologic practice and is being integrated with conventional ...
0 comments

Melanoma CPG Update v3.1 Now Available

By SITC Scientific Publications News posted 05-20-2024
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments

SITC Publishes Recommendations  on Intratumoral Immunotherapy Clinical Trial Design

By SITC Scientific Publications News posted 04-19-2024
On behalf of the society and the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group, we are pleased to announce the publication of a new manuscript “ Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease ” in the Journal for ImmunoTherapy of Cancer . While intratumoral immunotherapies have the potential to boost anti-tumor ...
0 comments

Meet JITC’s Incoming Editor-in-Chief – Michael T. Lotze, MD

By JITC Publications posted 04-15-2024
Dr. Michael T. Lotze is Incoming Editor-in-Chief for the Journal for ImmunoTherapy of Cancer ( JITC ). As he transitions into his role with JITC , learn more about Dr. Lotze’s career, interest in JITC , and personal life. Career What inspired you to become a researcher? Dr. Lotze: My earliest experiences in research were a disaster; I worked on a project at Northwestern University over the summer after ...
0 comments

Nonmelanoma Skin Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 03-19-2024
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments

Announcing SITC's 2024 Advances in Cancer Immunotherapy Series

By SITC Scientific Publications News posted 03-15-2024
SITC 2024 Advances in Cancer Immunotherapy Series We’re excited to announce SITC’s 2024 Advances in Cancer Immunotherapy (ACI) educational series, which offers in-depth clinical training in immunotherapy treatment for a variety of disease states and topics from experts in the field. The ACI programs aim to engage practicing clinical oncologists, advanced practitioners, nurses, pharmacists, emergency physicians, and other allied health professionals ...
0 comments

New SITC Melanoma CPG Published in JITC

By SITC Scientific Publications News posted 10-18-2023
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Melanoma Guideline Expert Panel, we are pleased to announce the publication of SITC’s Melanoma Clinical Practice Guideline (CPG), version 3.0. This manuscript is SITC’s first CPG covering immunotherapy indications for cutaneous melanoma as well as rarer subtypes of the disease. Immunotherapy is a standard of care option for both BRAF -wildtype and BRAFV600 -mutated ...
0 comments

New SITC-IBCG Bladder Cancer Clinical Trial Design Recommendations Article Published in JCO

By SITC Scientific Publications News posted 10-04-2023
On behalf of the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG), we are pleased to announce the publication of the “ Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group ,” in the Journal of Clinical Oncology. These recommendations provide a detailed clinical trial design guide ...
0 comments

Hepatocellular Carcinoma CPG Update v1.1(A) Now Available

By SITC Scientific Publications News posted 09-01-2023
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments

New SITC Gynecologic Cancer CPG Published in JITC

By SITC Scientific Publications News posted 06-09-2023
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Gynecologic Cancer Immunotherapy Guideline Expert Panel, we are pleased to announce the publication of SITC’s Gynecologic Cancer Clinical Practice Guideline (CPG). This manuscript is SITC’s first CPG covering immunotherapy indications for cervical, endometrial, and ovarian cancer, as well as other rare gynecologic cancers. The treatment landscape in gynecologic cancers is ...
0 comments

New SITC Gastrointestinal Cancer CPG Published in JITC

By SITC Scientific Publications News posted 06-07-2023
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. " Clinicians will find this guideline an invaluable resource to assist in navigating the challenging issues that sometimes arise during the treatment of gastrointestinal cancer, including treatment selection based on histology and biomarker status, ...
0 comments

SITC Publishes Consensus Definitions for Immune Checkpoint Inhibitor-Related Adverse Events Terminology

By SITC Scientific Publications News posted 04-04-2023
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid tumors, providing deep and durable responses for many patients. However, the anti-tumor mechanism of action of ICIs can also cause aberrantly active self-damaging immune responses, leading to immune-related adverse events (irAEs). The natural history, response to treatment, and patterns of irAEs vary widely, ranging from short-term inflammatory conditions to prolonged ...
0 comments

New SITC consensus definitions for resistance to combinations of immune checkpoint inhibitors published in JITC

By SITC Scientific Publications News posted 03-14-2023
The Society for Immunotherapy of Cancer (SITC) hosted the "Combination Immunotherapy Resistance Workshop" with the purpose of bringing together immunotherapy experts from across academia, government, and industry to reach consensus on definitions of IO resistance to accelerate drug development. Consensus resistance definitions from the workshop have recently been published in the Journal for ImmunoTherapy of Cancer ( JITC ) via three manuscripts, ...
0 comments